Showing 1153–1168 of 5741 results

MCC950 (CP-456773)

MCC950 sodium salt is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs but not the AIM2, NLRC4 or NLRP1 inflammasomes.

AT7519 HCl

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.

FRAX486

FRAX486 is a potent p21-activated kinase (PAK) inhibitor with IC50 values of 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively.

EPZ011989

EPZ011989 is a potent, selective, orally bioavailable EZH2 inhibitor with Ki of <3 nM.

GSK503

GSK503 is a potent and specific EZH2 methyltransferase inhibitor.

A-1331852

A-1331852 is a potent and selectiveBCL-XL inhibitor with Ki value less than 0.01 nM for BCL-XL and 6 nM, 4 nM, 142 nM for Bcl-2, Bcl-W, MCL-1 respectively. It may be useful in the treatment of cancer, immune and autoimmune diseases.

1235034-55-5 Chemical Structure

A-1155463

A-1155463, a highly potent and selective BCL-XL inhibitor, shows picomolar binding affinity to BCL-xL, and >1000-fold weaker binding to BCL-2 and related proteins BCL-W (Ki=19 nM) and MCL-1 (Ki>440 nM).

Pexmetinib (ARRY-614)

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.

GNE-317

GNE-317 is a potent, brain-penetrant PI3K inhibitor.

GSK2879552 2HCl

GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1.

ORY-1001 (RG-6016) 2HCl

ORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.

Purvalanol A

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

SRT2104 (GSK2245840)

SRT2104 (GSK2245840) is a selective SIRT1 activator involved in the regulation of energy homeostasis. Phase 2.

A-1210477

A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

Docetaxel Trihydrate

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.